Tom Gallen
Managing Editor, Europe

Latest From Tom Gallen
Kidney Inflammation Warning For PPI Omeprazole In Europe
Cases of acute tubulointerstitial nephritis linked to omeprazole use flagged to the EMA leads to new product information warnings related to a possible risk of kidney inflammation for drugs containing the PPI sold in the EU.
France Expanded Free Access Scheme In 2022 With OTC, Herbal And Homeopathic Additions
Record of OTC drugs, traditional herbal medicines and homeopathic medicines added to France's "free access" pharmacy self-selection scheme in 2022.
UK Rejects Blood Glucose Health Claim For White Mulberry Supplement
The UK Nutrition and Health Claims Committee has rejected the health claim “clinically proven in assisting healthy blood glucose levels” in the target population of type 2 diabetics for Ascarit’s white mulberry-based dietary supplement.
Alliance Pharma Has High Hopes For Recovering Chinese Market in 2023
Alliance Pharma is hopeful the end to COVID-19 movement restrictions in China will help to boost demand for its key consumer health brands Kelo-cote and Nizoral in 2023.
Boiron's Sales Grow Double-Digits In 2022 Despite Difficult End To Year
French homeopathy specialist Boiron enjoyed a good 2022 after a few challenging years as a result of COVID-19 and France's decision to exclude homeopathic medicines from health insurance coverage.
Euro Q4 Consumer Health Earnings Preview: Sanofi, Bayer, Reckitt And Haleon
Major Europe-based consumer health players Sanofi Bayer, Reckitt and Haleon feature in this sales and earnings preview, which highlights what to look out for as these four firms report their Q4 2022 results over the coming weeks.